B-cell involvement supports anti-CD20 therapy in paediatric rheumatic heart disease: Proof of concept and initial safety

Rheumatic heart disease (RHD) remains a major cause of cardiovascular morbidity and mortality, particularly in low- and middle-income countries, yet no therapy targets its underlying autoimmune mechanisms. We combined transcriptomic analyses of rheumatic mitral valves tissues with a translational approach. Using a panel of 750 mRNAs, we found a marked upregulation of B-cell-related pathways, including CD20-associated and multiple immunoglobulin genes, supporting a pathogenic role of B cells in RHD. We therefore evaluated an anti-CD20 B-cell depleting monoclonal antibody (Rituximab), in a feasibility study in children with RHD, in Dakar, Senegal. Treatment was well tolerated, and in the following RCT first year preliminary safety analysis asked by the ethical committee, children who received rituximab showed a decrease in anti-streptolysin O titers and clinical improvement compared to controls. This proof-of-concept reveals B cells as a therapeutic target and suggests that an anti-CD20 agent may represent a potential disease-modifying therapy for RHD.

Authors

Institutions

Publication Details

Journal
medRxiv
Published
2026-11-17
DOI
https://doi.org/10.64898/2026.11.17.26367998
Primary Topic
Streptococcal Infections and Treatments
Type
preprint
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

B-cell involvement supports anti-CD20 therapy in paediatric rheumatic heart disease: Proof of concept and initial safety

Ibrahima Bara Diop, Lamine Sy, Halifa Farchati, Alexandre Loupy et al.
medRxiv
Streptococcal Infections and Treatments
preprint

B-cell involvement supports anti-CD20 therapy in paediatric rheumatic heart disease: Proof of concept and initial safety

Ibrahima Bara Diop, Lamine Sy, Halifa Farchati, Alexandre Loupy, Marie Antignac, Ndeye Awa Sarr, Olivier Hermine, Wolf H. Fridman, P Bruneval, Amadou Lamine Fall, Xavier Jouven, Emma Menant, Hanifa Ismael, Magalie Kaya Samba, Hafid Ait Oufella, Elisabeth Tine
preprint en

Abstract

Rheumatic heart disease (RHD) remains a major cause of cardiovascular morbidity and mortality, particularly in low- and middle-income countries, yet no therapy targets its underlying autoimmune mechanisms. We combined transcriptomic analyses of rheumatic mitral valves tissues with a translational approach. Using a panel of 750 mRNAs, we found a marked upregulation of B-cell-related pathways, including CD20-associated and multiple immunoglobulin genes, supporting a pathogenic role of B cells in RHD. We therefore evaluated an anti-CD20 B-cell depleting monoclonal antibody (Rituximab), in a feasibility study in children with RHD, in Dakar, Senegal. Treatment was well tolerated, and in the following RCT first year preliminary safety analysis asked by the ethical committee, children who received rituximab showed a decrease in anti-streptolysin O titers and clinical improvement compared to controls. This proof-of-concept reveals B cells as a therapeutic target and suggests that an anti-CD20 agent may represent a potential disease-modifying therapy for RHD.

medRxiv
Hôpital Necker-Enfants Malades (FR), Inserm (FR), Université Paris Cité (FR), Sorbonne Université (FR), Centre de Recherche des Cordeliers (FR), Assistance Publique – Hôpitaux de Paris (FR), Paris Cardiovascular Research Center (FR), Centre Hospitalier National Universitaire de Fann (SN), Université Pierre-et-Marie-Curie (FR)
Good health and well-being
Streptococcal Infections and Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon